Founded in 2022, India's Vivint Pharma plans to spend 400 crore rupees (about $48 million) to build an injectables manufacturing facility in Hyderabad, India. The company plans to employ up to 1,000 workers at the site.
The facility will be the first production plant for Vivint and will be located on 5.5 acres in what is dubbed "Genome Valley" in Hyderabad, Telangana. Vivint currently operates a R&D facility near the site, according to an Aug. 7 press release.
The date for the projected completion of the facility—and its planned square footage—were not disclosed.
“I am delighted to note about Vivint Pharma’s investment in Genome Valley,” Sri Revanth Reddy, chief minister of Telangana, said in the release. “Telangana has always been at the forefront of fostering innovation in the life sciences sector, and this investment will add further impetus.”
The project is part of the company’s push to expand its presence in India.
When completed, the facility will concentrate on developing and producing injectable drugs in the oncology and critical care spaces for both domestic and international markets.